Chemical Properties
IC-26 acts primarily as an agonist at the μ-opioid receptors in the central nervous system, producing analgesic (pain-relieving) and sedative effects. Compared to methadone, IC-26 shows comparable potency, but there is evidence that effects may be inconsistent in different patients, requiring different dosages. In controlled studies, IC-26 has been found to have a lower propensity for respiratory depression, a common and dangerous risk with many opioids.
Origin and Structure
IC-26, also known as methiodone or WIN 1161-3, is a research chemical in the opioid group. It is an analogue of methadone, with the carbonyl group replaced by a bioisosteric sulfone group. This structural modification results in a similar mode of action to methadone, but with some differences in potency and pharmacological properties.
Due to its potential risks, particularly in terms of developing addiction, IC-26 has never been approved as a drug and remains relevant primarily in research and forensic applications. It is mainly used for scientific studies to explore new approaches in pain therapy and to minimize the risk of opioid addiction.
Important legal notice
The legal status of IC-26 is not clearly defined, and it is not internationally classified as a controlled substance, which allows its use in certain scientific circles.
Not for human use!
We emphasize that IC-26 is not sold for human use. Any use should only be within the framework of research and development work that complies with applicable laws, guidelines and ethical standards.
Not for sale to persons under 18 years of age.
For more information or specific inquiries, please contact our customer service.